



Docket No.: 203975US0X

TECH CENTER 1600/2900

OBLON

SPIVAK McClelland

MAIER

NEUSTADT P.C.

ATTORNEYS AT LAW

NORMAN F. OBLON (703) 413-3000 NOBLON@OBLON.COM

VINCENT K. SHIER, PH.D.

REGISTERED PATENT AGENT (703) 413-3000

VSHIER@OBLON.COM

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

RE: Application Serial No.: 09/903,771

Applicants: Bettina MOECKEL, et al.

Filing Date: July 13, 2001

For: NUCLEOTIDE SEQUENCES CODING FOR THE

LUXR GENE Group Art Unit: 1652

Examiner: Kathleen M. KERR

SIR:

Attached hereto for filing are the following papers:

Response to Restriction Requirement

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Registration No. 24,618

Vincent K. Shier, Ph.D. Registration No. 50,552

(703) 413-3000 (phone) (703) 413-2220 (fax)

DOCKET NO.: 203975US0X

1 6 2002 # 8/1RX

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF:

Bettina MOECKEL, et al.

: GROUP ART UNIT: 1652

RECEIVED

SERIAL NO.: 09/903,771

OCT 1 7 2002

FILED: JULY 13, 2001

: EXAMINER: KERR

TECH CENTER 1600/2900

FOR: NUCLEOTIDE SEQUENCES WHICH CODE FOR THE luxR GENE

RESPONSE TO RESTRICTION REQUIREMENT

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Responsive to the Official Action dated September 19, 2002, Applicants elect, with traverse, Group I, Claims 1-19 and 37-38, for further prosecution.

REMARKS

The Office has required restriction in the present application as follows:

Group I:

Claims 1-19 and 37-38, drawn to polynucleotides encoding a luxR transcriptional activation gene, vectors, host cells, and methods of

making a luxR protein;

Group II:

Claims 20-21, drawn to Corynebacterium with an attenuated luxR

gene;

Group III:

Claim 22, drawn to E. coli with a plasmid containing an attenuated

luxR gene;

Group IV:

Claims 23-30, drawn to methods for making amino acids;

Group V:

Claims 31-36, drawn to hybridization methods; and

Group VI:

Claim 39, drawn to a luxR protein.